Skip to Main Content
Table 2—

The association of baseline clinical parameters and lipid variables with progression in patients with microalbuminuria

NonprogressorsProgressors
n 25 15 
Baseline AER (geometric mean) (μg/min) 52 50 
End point AER (geometric mean) (μg/min) 35 407 
Baseline CrCl (ml/min per 1.73 m284 ± 3 74 ± 4* 
End point CrCl (ml/min per 1.73 m277 ± 4 57 ± 5* 
Sex (% male) 66 40 
HbA1c (%) 8.1 ± 0.3 8.5 ± 0.3 
Blood pressure (mmHg) 129/80 ± 4/2 133/81 ± 4/1 
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.2 ± 0.3 
Non-HDL cholesterol (mmol/l) 3.6 ± 0.2 3.8 ± 0.3 
Triglycerides (mmol/l) 1.12 ± 0.08 1.13 ± 0.12 
HDL cholesterol (mmol/l) 1.6 ± 0.1 1.4 ± 0.1 
VLDL triglyceride content (%) 47 ± 1 54 ± 2* 
IDL triglyceride content (%) 25 ± 1 32 ± 2* 
VLDL mass (mg/dl) 89 ± 16 107 ± 12 
IDL mass (mg/dl) 41 ± 5 47 ± 7 
VLDL triglycerides (mmol/l) 0.52 ± 0.11 0.57 ± 0.07 
LPL15 (μmol FFA · ml−1 · h−135 ± 2 39 ± 4 
HL15 (μmol FFA · ml−1 · h−130 ± 3 31 ± 3 
NonprogressorsProgressors
n 25 15 
Baseline AER (geometric mean) (μg/min) 52 50 
End point AER (geometric mean) (μg/min) 35 407 
Baseline CrCl (ml/min per 1.73 m284 ± 3 74 ± 4* 
End point CrCl (ml/min per 1.73 m277 ± 4 57 ± 5* 
Sex (% male) 66 40 
HbA1c (%) 8.1 ± 0.3 8.5 ± 0.3 
Blood pressure (mmHg) 129/80 ± 4/2 133/81 ± 4/1 
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.2 ± 0.3 
Non-HDL cholesterol (mmol/l) 3.6 ± 0.2 3.8 ± 0.3 
Triglycerides (mmol/l) 1.12 ± 0.08 1.13 ± 0.12 
HDL cholesterol (mmol/l) 1.6 ± 0.1 1.4 ± 0.1 
VLDL triglyceride content (%) 47 ± 1 54 ± 2* 
IDL triglyceride content (%) 25 ± 1 32 ± 2* 
VLDL mass (mg/dl) 89 ± 16 107 ± 12 
IDL mass (mg/dl) 41 ± 5 47 ± 7 
VLDL triglycerides (mmol/l) 0.52 ± 0.11 0.57 ± 0.07 
LPL15 (μmol FFA · ml−1 · h−135 ± 2 39 ± 4 
HL15 (μmol FFA · ml−1 · h−130 ± 3 31 ± 3 

Data are means ± SE unless otherwise indicated.

*

Progressors vs. nonprogressors, univariate P < 0.05.

Progressors vs. nonprogressors, adjusted P < 0.05. CrCl, creatinine clearance; FFA, free fatty acid; HL15, hepatic lipase 15 min after an intravenous bolus of heparin; LPL15, lipoprotein lipase 15 min after an intravenous bolus of heparin.

Close Modal

or Create an Account

Close Modal
Close Modal